Last reviewed · How we verify
HX111 for injection — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HX111 for injection (HX111 for injection) — Hanx Biopharmaceuticals (Wuhan) Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HX111 for injection TARGET | HX111 for injection | Hanx Biopharmaceuticals (Wuhan) Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HX111 for injection CI watch — RSS
- HX111 for injection CI watch — Atom
- HX111 for injection CI watch — JSON
- HX111 for injection alone — RSS
Cite this brief
Drug Landscape (2026). HX111 for injection — Competitive Intelligence Brief. https://druglandscape.com/ci/hx111-for-injection. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing